Antibody Drug Developer Kymab Snags $100M From Investors
Kymab Group Ltd., a developer of monoclonal antibody therapeutics meant to stimulate the body's natural immune system to fight cancer, has raised $100 million from a group of private investors led...To view the full article, register now.
Already a subscriber? Click here to view full article